<DOC>
	<DOCNO>NCT00695903</DOCNO>
	<brief_summary>The overall goal study compare safety efficacy daptomycin monotherapy 10 mg/kg/day vancomycin monotherapy dose achieve vancomycin trough level 15 20 μg/mL treatment methicillin-resistant S. aureus bacteremia ( MRSA ) , include right-sided infective endocarditis ( RIE ) .</brief_summary>
	<brief_title>Phase 2 Study Safety , Efficacy , Pharmacokinetics Higher Doses Daptomycin Vancomycin MRSA Bacteremia</brief_title>
	<detailed_description>Patients meet inclusion criterion exhibit none exclusion criterial randomize one two treatment arm : 1. daptomycin Intravenously ( IV ) 10 mg/kg every 24 hour 2. vancomycin IV dose maintain trough level 15 20 μg/mL . The suggested duration therapy daptomycin vancomycin 28 day ( 42 day clinically indicate ) . Dose adjustment drug make unblinded pharmacist site . To minimize duration patient treat antibacterial agent effective S. aureus prior enrollment , patient suspect MRSA bacteremia enrol pending definitive culture result . Suspected MRSA bacteremia define clinically initial blood culture grow Gram-positive cocci obtain patient increase risk methicillin-resistant S. aureus infection . However , patient confirm MRSA bacteremia right-sided infective endocarditis remain study evaluate efficacy . During treatment , regular assessment perform . An End-of Therapy ( EOT ) perform 1-3 day stop therapy upon Early Termination ( ET ) . All patient post therapy visit Test Cure ( TOC ) perform 35-49 day follow last dose study drug .</detailed_description>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Endocarditis</mesh_term>
	<mesh_term>Endocarditis , Bacterial</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>INCLUSION CRITERIA : Written inform consent obtain ; ≥18 year age ; Suspected MRSA bacteremia determine clinical judgment 2 set positive blood culture ; Increased risk MRSA infection EXCLUSION CRITERIA : Received &gt; 48 hour vancomycin therapy 7 day prior enrollment ; Received systemic antibacterial agent potentially effective MRSA 7 day prior enrollment ; Anticipated requirement antibiotic potentially effective MRSA ; High likelihood leftsided infective endocarditis ( LIE ) ; Known/suspected polymicrobial bacteremia infection include Gramnegative infection ; Known pneumonia , osteomyelitis , meningitis ; Intravascular foreign material unless material intend remove within 3 day ; Prosthetic heart valve ; Cardiac decompensation , valve damage , high likelihood valve replacement surgery within first 3 day study drug treatment ; Moribund clinical condition death likely within first 3 day study drug treatment ; Shock hypotension oliguria unresponsive fluid 4 hour ; Received investigational drug within 30 day study entry Received statins therapy associate rhabdomyolysis within 2 day study entry ; History significant allergy intolerance vancomycin daptomycin Infecting pathogen confirm reduced susceptibility vancomycin ; Infecting pathogen confirm reduced susceptibility daptomycin Creatinine clearance &lt; 30 mL/min ( CockcroftGault equation actual body weight ) Serum creatine phosphokinase ( CPK ) ≥500 U/L Alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) &gt; 5 X ULN ; Total bilirubin ≥3.0 mg/dL ; Severe neutropenia expect development severe neutropenia study ; Known suspect HIV infection CD4+ Tcell count &lt; 200/μL ; Unlikely comply study procedure return evaluation ; Body Mass Index ( BMI ) ≥40 kg/m2 ; Pregnant nursing ; Female childbearing potential willing practice barrier method birth control . CONTINUATION CRITERIA : Fulfills A B : A ) Confirmed complicate MRSA bacteremia B ) Possible definite RIE cause MRSA accord modify Duke criterion ; Infecting S. aureus strain susceptible vancomycin ; Infecting S. aureus strain susceptible daptomycin ; Appropriate treatment focus infection within first 3 day study ; Removal intravascular foreign material allow per inclusion criterion within first 3 day study ; Removal percutaneous implant catheter allow per inclusion criterion within first 3 day study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Gram-positive bacterial infection</keyword>
	<keyword>Staph Aureus</keyword>
	<keyword>Bacteremia</keyword>
	<keyword>MRSA</keyword>
	<keyword>Infective Endocarditis</keyword>
	<keyword>Right-sided Infective endocarditis</keyword>
	<keyword>SABIE</keyword>
	<keyword>SAIE</keyword>
	<keyword>RIE</keyword>
</DOC>